Tridek-One
A spin-off from INSERM, this biotech company develops first-in-class CD31-ITAM immune modulating bispecific antibodies to treat autoimmune and inflammatory diseases. Its technology platform leverages CD31 ITIM receptor agonism to selectively target pathogenic immune cells and restore immune balance. The pipeline focuses on antibodies with IgG-like pharmacokinetic features for patients with various immune disorders.
Visit websiteParis, France
Biotech
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €16.1M
- Funding rounds
- 1
Investors in Tridek-One
Investors on record for Tridek-One. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Tridek-One?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors